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Abstract 
Researchers have recently explored transdiagnostic anxiety treatments based on models of anxiety 
emphasizing a single common pathway across diagnostic categories. Results from a previous study 
(Norton and Hope, in press) indicated that a transdiagnostic approach was effective for both targeted 
and untargeted anxiety disorders. Consistent with the tripartite model, the transdiagnostic treatment 
should also influence symptoms of a broader pathology such as negative affectivity. This follow-up 
to Norton and Hope found significant decreases in depressed mood for clients undergoing transdi-
agnostic treatment for anxiety when compared to wait-list control participants. Although not statis-
tically established, severity of depressive diagnoses seemed to generally decrease across treatment, 
whereas no change in severity occurred for those not receiving treatment. 
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Introduction 
 
Anxiety disorders rate among the most treatable psychological conditions. Meta-analyses 
of psychological and pharmacological treatments consistently show strong treatment ef-
fects of cognitive-behavioral treatments (CBT) and various pharmacological agents for 
anxiety disorders (Deacon and Abramowitz, 2004). Despite this, calls have been made for 
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the development of innovative but theoretically driven and evidence-based treatment ap-
proaches that will augment dissemination and accessibility (Office of the Surgeon General, 
1999; Persons, 2003). In response to these calls, exploration has begun (Barlow et al., 2003; 
Erickson, 2003; Norton and Hope, in press; White-Lumpkin et al., 2002) on exploring trans-
diagnostic approaches to anxiety treatment. These transdiagnostic anxiety treatments are 
based on models of anxiety, such as the Clark and Watson (1991) tripartite model, that 
emphasize a single common pathology across the diagnostic categories as opposed to the 
DSM-IV implication of distinct disease states. These models hold that this core pathology 
(“negative affectivity”) is not specific to anxiety but is also involved in depression (Clark 
and Watson, 1991; Eysenck, 1957). 
In the only randomized, controlled trial of a transdiagnostic anxiety treatment con-
ducted, to our knowledge, to date, Norton and Hope (in press) evaluated the efficacy of a 
12-week group treatment among a sample of 23 individuals diagnosed with a range of 
anxiety disorders. Treatment included psychoeducation (1.5 sessions), cognitive restruc-
turing (3.5 sessions), exposure and response prevention with feared stimuli whether via in 
vivo, role-played, imaginal, or interoceptive methods (6 sessions), and relapse prevention 
(1 session). Results of this trial provided preliminary support of the efficacy of the transdi-
agnostic treatment. Compared to waitlist controls, individuals completing treatment were 
less likely to meet diagnostic criteria for an anxiety disorder and had improved signifi-
cantly on diagnostic severity measures and individualized fear-avoidance hierarchies. 
Currently, a multisite randomized controlled trial of a similar transdiagnostic anxiety 
treatment is being conducted in Canada. Although this project is not completed, prelimi-
nary data (Laposa et al., 2003) seem promising. In addition, others (Barlow et al., 2003; 
Erickson, 2003; Larkin et al., 2003; Schmidt, 2003; White Lumpkin et al., 2002) have con-
ducted uncontrolled pre-post evaluations of similar transdiagnostic protocols and re-
ported significant anxiety symptom reduction during treatment. 
If the premise of a common core pathology is valid, and it is this pathology that is being 
targeted in cognitive-behavioral treatment (CBT), it should follow that CBT acting upon 
the core pathology should impact not only the targeted anxiety disorders but also untar-
geted secondary diagnoses related to negative affectivity. Studies have shown that despite 
targeting a primary anxiety diagnosis (PTSD [Blanchard et al., 2003], Generalized Anxiety 
Disorder [Borkovec et al., 1995], Panic Disorder [Brown et al. 1995; Tsao et al., 1998, 2002]), 
untargeted secondary anxiety diagnoses remitted or abated. Norton and Hope (in press) 
found that the aforementioned transdiagnostic anxiety treatment impacted not only pri-
mary anxiety diagnoses, but also significantly reduced the severity of secondary anxiety 
diagnoses. These results support the claim that CBT for anxiety disorders is effective for 
anxiety disorders in general, targeted or otherwise. Less evidence, however, is available 
regarding the effect of CBT for anxiety disorders on negative affect-related disorders in 
general. Blanchard et al. (2003) reported a decrease in comorbid depression after treatment 
for PTSD, although Brown et al. (1995) reported no such decline in comorbid depressive 
diagnoses after treatment for panic disorder. Tsao et al. (1998) reported a decline in comor-
bid depressive diagnoses after panic treatment, although this decline was smaller than that 
observed for comorbid anxiety diagnoses. 
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The purpose of this study was to examine the impact of a transdiagnostic anxiety treat-
ment on negative affect-related disorders more generally by focusing on the treatment’s 
influence on depressed mood and secondary depressive disorders. 
 
Participants and Methods 
 
Participants 
Twenty-three individuals (60.9% women) meeting DSM-IV criteria for an anxiety disorder 
were recruited for participation in an anxiety treatment outcome study. Of these individ-
uals, five had a clinically significant secondary diagnosis of major depression and three 
had a clinically significant secondary diagnosis of dysthymia. For inclusion in the study, 
participants were required to be (1) age 19 or older, (2) have primary DSM-IV diagnosis of 
an anxiety disorder, (3) demonstrate adequate proficiency in English, (4) be willing to ac-
cept random assignment, (5) be able to provide informed consent, and (6) show no evi-
dence of serious suicidality, substance abuse, or other condition that would require 
immediate intervention. Participants who attended 75% or fewer of the sessions were con-
sidered to be dropouts. Four participants (three in immediate treatment), all women, 
dropped out from the study, yielding a final sample of 19. None of those who dropped out 
had comorbid depressive diagnoses. Primary anxiety diagnoses included panic disorder 
with or without agoraphobia (n = 3), social anxiety disorder (n = 5), obsessive-compulsive 
disorder (n = 3), generalized anxiety disorder (n = 7), and posttraumatic stress disorder (n = 1). 
Ten of the completers were also receiving medication for their anxiety and were asked 
to provide a release to contact the prescribing physician. The participant and physician 
were informed of the general nature of the study and their agreement was sought to at-
tempt to maintain the person on the same dosage and medications throughout the 12 
weeks of active treatment. The participant was asked to inform his therapist of any medi-
cation adjustments the physician deems to be medically necessary during the course of the 
study. No medication changes were reported over the course of the treatment, save for one 
participant who successfully discontinued PRN benzodiazepine use. A full description of 
the sample is provided in detail elsewhere (Norton and Hope, in press). 
 
Measures 
All participants received a comprehensive assessment, consisting of a structured diagnos-
tic interview and self-report questionnaires, at both pre- and post-treatment. One partici-
pant with a comorbid diagnosis of major depressive disorder completed questionnaires at 
post-treatment but did not return for a posttreatment structured diagnostic interview. 
 
Anxiety Disorders Interview Schedule for DSM-IV 
The Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) (Brown et al., 1994) is a 
semistructured diagnostic interview designed to assess the presence, nature, and severity 
of DSM-IV anxiety, mood, and somatoform disorders. ADIS-IV interviewers, advanced 
doctoral students, and a licensed clinical psychologist were trained to rigorous standards 
for reliability with an expert ADIS interviewer. Because of practical constraints, ADIS in-
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terviewers were not consistently blind to treatment condition or assessment point. Clini-
cian Severity Ratings (CSR), subjective ratings to quantify the degree of severity for each 
diagnosis, were applied to each diagnosis. CSR range from 0 (not at all severe) to 8 (ex-
tremely severe/distressing), and a CSR of 4 (moderate impairment) is generally considered 
the cut-off for clinical significance. 
 
Depression, Anxiety, And Stress Scales 
The Depression, Anxiety, and Stress Scale (DASS) (Lovibond and Lovibond, 1993) is a 42-
item self-report measure assessing the unique aspects of anxiety and depression as well as 
the common shared element of negative affectivity. The convergent and discriminant va-
lidity of the DASS subscales has also been consistently demonstrated. The Depression sub-
scale correlates strongly with the Beck Depression Inventory, and the Anxiety subscale 
correlates strongly with Beck Anxiety Inventory, but the Depression and Anxiety subscales 
correlate only moderately with the nonrespective Beck Inventories (Antony et al., 1998; 
Brown et al., 1997; Lovibond and Lovibond, 1995). Furthermore, the Anxiety and Depres-
sion subscales significantly differentiate between patients with anxiety diagnoses or de-
pressive diagnoses (Antony et al., 1998; Brown et al., 1997). 
 
Mood and Anxiety Symptom Questionnaire 
The Mood and Anxiety Symptom Questionnaire (MASQ) (Watson and Clark, 1991) is a 
reliable and valid (Keogh and Reidy, 2000) 90-item self-report measure also developed to 
assess the components of the tripartite model. The subscales of the MASQ were designed 
to be highly discriminative among anxiety, depression, and their common features. Con-
sistent with predictions from the tripartite model, the nonspecific subscale tapping nega-
tive affectivity correlated moderately with both the somatic anxiety subscale (r = .58) and 
positive affect/anhedonia subscale (r = .58) whereas the correlation between the anxiety- 
and depression-specific factors was low (r = .23) (Keogh and Reidy, 2000). Estimates of 
convergent validity have shown that the anxiety-specific and depression-specific subscales 
relate strongly to other self-report measures of anxiety symptoms and depressive symp-
toms, respectively (Watson et al., 1995a,b). 
 
Procedure 
The study was conducted at the Anxiety Disorders Clinic of the University of Nebraska–
Lincoln. Participants meeting inclusion criteria completed the questionnaires and were as-
sessed by a trained diagnostician using the ADIS-IV. Participants were then assigned to 
either the immediate treatment condition or delayed treatment condition, using block ran-
domization by primary diagnosis. After the treatment and delay periods, all participants 
were reassessed with the ADIS-IV and the same questionnaires. Details of the research 
design and treatment protocol are described in Norton and Hope (in press). 
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Results 
 
As an initial test of the impact of the anxiety treatment on depressed mood, a 2 (Time: pre- 
vs. post-treatment) × 2 (Condition: immediate vs. delayed treatment) MANOVA, with re-
peated measures on the first factor, was computed using the Anhedonic Depression sub-
scale of the MASQ and the Depression subscale of the DASS as the dependent variables. 
Significant main effects of Time, F(2, 16) = 6.21, P = .01, and Condition, F(2, 16) = 4.07, P = .04, 
were observed. The main effects, however, were modified by a significant Time × Condi-
tion interaction, F(2, 16) = –3.64, P = .05. Analysis of the interaction at a univariate level, 
using separate 2 (Time: pre- vs. post-treatment) × 2 (Condition: immediate vs. delayed 
treatment) ANOVA, indicated that participants in the immediate treatment condition im-
proved on the MASQ-AD whereas no change was observed for waitlist control partici-
pants, F(1, 17) = 7.50, P = .01, d = 1.33. A nearly significant trend in the same pattern was 
observed for the DASS-D, F(1, 17) = 4.06, P = .06, D = 0.98 (Fig. 1 and Table 1). 
 
 
 
Figure 1. Change in self-reported depression by treatment condition. 
 
Table 1. Change in self-reported depression by treatment condition 
 Pre-Tx Post-Tx Pre-Tx Post-Tx 
Immediate 92.11 (5.17) 71.67 (5.60) 16.44 (4.24) 5.44 (3.49) 
Delayed 93.00 (4.91) 91.00 (5.32) 25.70 (4.02) 23.30 (3.31) 
Values are expressed as mean (sd). 
 
ADIS CSR for Depressive Diagnoses were examined next. Only eight participants had 
an initial diagnosis of a depressive disorder. Therefore, due to the unacceptably low statis-
tical power, the data were visually inspected but not statistically analyzed. Visual inspec-
tion (Fig. 2) of change in CSR shows that the depression CSR rating for three of four 
participants in the treatment condition improved to subclinical levels (CSR = < 4). In con-
trast, none of the participants in the control condition improved or worsened during the 
waitlist period. One participant receiving treatment showed a marked increase in depres-
sive severity, such that depression became the primary concern, and significant marital 
difficulties became critical during this time. 
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Figure 2. Change in individual ADIS clinician severity ratings of depressive diagnoses. 
 
Discussion 
 
The results of this study generally support the presumption that CBT for anxiety may ac-
tually impact a broader pathology, such as negative affectivity. Although no depression-
specific techniques were introduced during treatment (such as behavioral activation, pleas-
ant event scheduling, or identification and challenging of depressive automatic thoughts or 
schemata), indices of depression decreased significantly for those receiving treatment in 
comparison to waitlist control participants. Although not statistically established, it also 
seems that the severity of depressive diagnoses generally decreased across treatment, 
whereas no change in depressive disorder severity occurred for those not receiving treatment. 
The results of these analyses may provide interesting support for the tripartite model 
(Clark and Watson, 1991) and other common pathology models of anxiety and depression 
(e.g., Eysenck, 1957). If clinical anxiety and depression were distinct disease entities, per-
haps linked only at a predispositional level, then this effect of the anxiety treatment on 
depressive symptoms would not be expected. Of course, additional research employing 
attention-control conditions will be required to rule out the possibility of nonspecific treat-
ment effects accounting for the changes in depressiveness. Furthermore, it is possible that 
the reduction in depressiveness may have resulted from other factors than changes in neg-
ative affectivity, such as decreased avoidance leading to greater behavioral activation. If 
the former, these data may suggest a preliminary affirmative response to Clark et al. (1994) 
question, “Can we treat the underlying personality variable rather than the specific mani-
fest disorder?” (p. 113). 
The principal limitation of this study is the limited sample size in general, and the very 
small number of individuals with comorbid depressive diagnoses in particular. The inter-
action effect sizes for indices of depression (d = 1.33 and 0.98) were similar to those we 
obtained on the indices of anxiety (Norton and Hope, in press) (d ≈ .75–1.44). Given that 
the DASS and MASQ were specifically designed to maximally discriminate anxiety and 
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depressive symptoms, it is unlikely that the similarity in effect on anxiety and depression 
was a function of symptom overlap or imprecise measurement. A second limitation of this 
study was that all of the measures were either based on direct client report or clinician 
ratings based on client interviews. This opens the possibility that the data may have been 
influenced to some degree by factors such as over- or under-reporting symptom severity, 
biased or distorted recall, and so forth. As noted earlier, diagnostic interviewers were not 
consistently blind to condition or assessment period. The similar pattern of change on self-
report outcome measures diminishes the credibility of experimenter bias effects as an ex-
planation for the observed treatment effects. 
One must be careful not to assume that CBT for anxiety represents a panacea for all 
negative affect spectrum disorders, nor should one infer that treating an anxiety disorder 
will automatically alleviate secondary depression. Clearly, much more research is neces-
sary to better understand the pathological targets impacted by treatment, and extent of 
diffusion of treatment gains to non-targeted concerns. These data, however, in conjunction 
with those of Blanchard et al. (2003), Borkovoc et al. (1995), Brown et al. (1995), and Tsao 
et al. (1998, 2002) do provide preliminary evidence suggesting that CBT targeted to anxiety 
may have an impact beyond the level of specific diagnoses or even diagnostic genus. Trans-
diagnostic treatments designed to target negative affect syndromes in general may prove 
valuable for more broadly mixed groups inclusive of all negative affect spectrum disor-
ders, including depressive disorders. Evaluations of this possibility are reportedly under-
way (Barlow et al., 2003). 
 
Acknowledgment – This research was supported by an NIMH Fellowship (1F31MH064227-01A1) 
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